生物活性
Quisinostat (JNJ-26481585)是一种新型的，二代HDAC抑制剂，对HDAC作用最有效，IC50为0.11 nM，适度有效作用于HDACs 2， 4， 10，和11；比作用于HDACs 3， 5， 8，和9选择性强30倍，对HDACs 6和7作用效果最弱。体外, JNJ-26481585有效抑制一组重组HDAC酶，最有效抑制HDAC1，IC50为 0.11 nM，另外抑制其他家族成员如HDAC2, 4, 10和 11时效果稍微低点，IC50分别为0.33 nM, 0.64 nM, 0.46 nM 和0.37 nM。 JNJ-26481585 作用于实体瘤和血癌细胞系，如肺癌，乳腺癌，结肠癌，前列腺癌，脑癌，和卵巢癌细胞系，IC50 为3.1 到 246 nM，具有广谱抗增殖活性，作用于多种人类癌细胞系时，JNJ-26481585效果比 Vorinostat, R306465, Panobinostat, CRA-24781, 和 Mocetinostat 好。 最新研究显示JNJ-26481585 在低纳摩尔浓度时通过耗尽Mcl-1及诱导Hsp72产生而促进骨髓癌细胞死亡。
化学数据
| 分子量 | 394.47 |
| 分子式 | C21H26N6O2 |
| CAS号 | 875320-29-9 |
| 纯度 | >98% |
| 溶解性（25°C） | DMSO 49 mg/mL |
| 储存和运输条件 | 固体粉末： -20°C 冷藏长期储存
常温运输及临时存放 |
实验操作 来自于公开的文献，仅供相同实验参考（如实验材料、目的不同，请参考其他文献）
| 细胞实验 |
|---|
| 细胞系 | colo-205, HT-29, HCT-116, H460, H1229, DU145, and A2780 cell lines |
| 方法 | Cell proliferation and apoptosis assays.
All cell lines were obtained from American Type Culture Collection and cultured according to instructions. The effect of HDAC inhibitors on cell proliferation was measured using an MTT as described (12). Proliferation of non–small cell lung carcinoma (NSCLC) cell lines was assessed using an Alamar Blue–based assay as described (12). For proliferation of hematologic cell lines, cells were incubated for 72 h and the cytotoxic activity was evaluated by MTS assay. Data are presented as mean IC50 or IC40 ± SD of at least three independent experiments. For apoptosis assays, human tumor cells were incubated for 24, 48, and 96 h with JNJ-26481585 at the indicated concentrations. Cells were stained for Annexin V and 7-AAD, according to the manufacturer's instructions and analyzed (Guava PCA-96 Nexin kit, Guava Technologies). The number of apoptotic and necrotic cells was expressed as a percentage of the total number of cells present in the well. Total cell number was expressed as a percentage of control, and the percentage of apoptotic/necrotic cells present in the absence of compound was subtracted from all values. All results shown are an average of three independent experiments (± SD). |
| 浓度 | 3, 10, 30, 100 and 300 nM |
| 处理时间 | 4 days |
| 动物实验 |
|---|
| 动物模型 | NMRI nude mice bearing colorectal cancer HCT-116 xenografts |
| 配制 | 20% hydroxypropyl-β-cyclodextrin (final pH 8.7) |
| 剂量 | 10 mg/kg once daily for 14 days |
| 给药处理 | i.p. |
不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）
| 小鼠 | 大鼠 | 兔 | 豚鼠 | 仓鼠 | 狗 |
| 重量 (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| 体表面积 (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km系数 | 3 | 6 | 12 | 8 | 5 | 20 |
| 动物 A (mg/kg) = 动物 B (mg/kg) × | 动物 B的Km系数 |
| 动物 A的Km系数 |
例如，依据体表面积折算法，将化合物用于小鼠的剂量20 mg/kg 换算成大鼠的剂量，需要将20 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到化合物用于大鼠的等效剂量为10 mg/kg。
储备液配制
以下数据基于产品分子量，对于特殊产品，请参照COA中的储备液配制条件和说明进行操作。
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.535 mL | 12.6752 mL | 25.3505 mL |
| 5 mM | 0.507 mL | 2.535 mL | 5.0701 mL |
| 10 mM | 0.2535 mL | 1.2675 mL | 2.535 mL |
